Chongqing Zhifei Biological Products Co., Ltd. (300122)

Basic

  • Market Cap

    CN¥149.38B

  • EV

    CN¥150.81B

  • Shares Out

    2,400M

  • Revenue

    CN¥49.71B

  • Employees

    5,735

Margins

  • Gross

    29.39%

  • EBITDA

    20.39%

  • Operating

    19.89%

  • Pre-Tax

    19.82%

  • Net

    17.02%

  • FCF

    4.98%

Returns (5Yr Avg)

  • ROA

    21.59%

  • ROE

    50.09%

  • ROCE

    58%

  • ROIC

    48.77%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    CN¥72.72

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    CN¥20.71

  • Earnings (Dil)

    CN¥3.53

  • FCF

    CN¥1.03

  • Book Value

    CN¥12.49

Growth (CAGR)

  • Rev 3Yr

    52.67%

  • Rev 5Yr

    64.97%

  • Rev 10Yr

    50.32%

  • Dil EPS 3Yr

    40.03%

  • Dil EPS 5Yr

    47%

  • Dil EPS 10Yr

    45.55%

  • Rev Fwd 2Yr

    25.33%

  • EBITDA Fwd 2Yr

    19.83%

  • EPS Fwd 2Yr

    23.07%

  • EPS LT Growth Est

    17.93%

Dividends

  • Yield

    —

  • Payout

    9.45%

  • DPS

    CN¥0.33

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    30.91%

  • DPS Growth 10Yr

    20.89%

  • DPS Growth Fwd 2Yr

    23.19%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Revenues

5,157.9

10,525.4

15,156.1

30,629.0

38,260.2

49,708.6

Other Revenues, Total

70.4

61.9

34.2

23.5

3.9

3.9

Total Revenues

5,228.3

10,587.3

15,190.4

30,652.4

38,264.0

49,712.4

Total Revenues % Chg.

289.4%

102.5%

43.5%

101.8%

24.8%

38.7%

Cost of Goods Sold, Total

2,381.3

6,154.0

9,315.8

15,727.8

25,518.3

35,101.0

Gross Profit

2,847.0

4,433.3

5,874.6

14,924.6

12,745.7

14,611.4

Selling General & Admin Expenses, Total

895.8

1,278.3

1,409.8

2,121.5

2,595.4

2,968.5

Provision for Bad Debts

60.5

68.1

82.9

190.7

420.9

733.4

R&D Expenses

142.9

169.6

299.7

552.6

854.2

895.2

Other Operating Expenses

28.4

51.4

71.0

135.2

177.0

128.0

Other Operating Expenses, Total

1,127.5

1,567.3

1,863.3

3,000.1

4,047.4

4,725.2

Operating Income

1,719.4

2,865.9

4,011.2

11,924.5

8,698.2

9,886.2

Interest Expense, Total

-27.0

-76.1

-127.1

-56.1

-53.3

-69.0

Interest And Investment Income

16.0

10.8

12.0

61.5

46.1

58.7

Net Interest Expenses

-11.1

-65.3

-115.2

5.3

-7.2

-10.3

Income (Loss) On Equity Invest.

—

—

—

—

—

—

Currency Exchange Gains (Loss)

2.3

1.9

3.8

-10.1

15.4

15.4

Other Non Operating Income (Expenses)

-9.4

-11.5

-19.6

-17.2

-22.6

-30.5

EBT, Excl. Unusual Items

1,701.3

2,791.1

3,880.3

11,902.5

8,683.8

9,860.8

Gain (Loss) On Sale Of Investments

—

-1.1

-13.3

-5.6

—

—

Gain (Loss) On Sale Of Assets

0.0

0.0

-0.0

0.0

0.0

43.0

Asset Writedown

-1.2

-0.7

-0.5

-1.7

-0.1

-83.7

Other Unusual Items

-7.8

-23.9

-12.3

35.8

34.3

34.3

EBT, Incl. Unusual Items

1,692.2

2,765.4

3,854.1

11,931.1

8,718.0

9,854.5

Income Tax Expense

240.9

398.9

552.7

1,722.5

1,179.0

1,392.4

Earnings From Continuing Operations

1,451.4

2,366.4

3,301.3

10,208.5

7,539.0

8,462.2

Net Income

1,451.4

2,366.4

3,301.3

10,208.5

7,539.0

8,462.2

Net Income to Common Incl Extra Items

1,451.4

2,366.4

3,301.3

10,208.5

7,539.0

8,462.2

Net Income to Common Excl. Extra Items

1,451.4

2,366.4

3,301.3

10,208.5

7,539.0

8,462.2

Total Shares Outstanding

2,400.0

2,400.0

2,400.0

2,400.0

2,400.0

2,400.0

Weighted Avg. Shares Outstanding

2,400.1

2,400.0

2,400.1

2,400.0

2,400.0

2,399.9

Weighted Avg. Shares Outstanding Dil

2,400.1

2,400.0

2,400.1

2,400.0

2,400.0

2,399.9

EPS

0.6

1.0

1.4

4.3

3.1

3.5

EPS Diluted

0.6

1.0

1.4

4.3

3.1

3.5

EBITDA

1,804.4

2,954.4

4,132.2

12,296.7

9,001.3

10,137.3